Regeneron Pharmaceuticals, Inc.
CorpDigest
Regeneron Pharmaceuticals, Inc.
Company History
Founded 1988 in Tarrytown, New York
Last reviewed: 2025-07-15 · By Swet Parvadiya
Regeneron Pharmaceuticals generated $14.3 billion in revenue for fiscal year 2025 while employing over 15,400 colleagues and maintaining a $66 billion market capitalization, yet the company's defining characteristic is not its scale but its scientific productivity, with nearly all 15 approved medicines discovered internally using proprietary platforms that have produced a higher ratio of approved drugs to clinical candidates than any comparable biotechnology company over the past two decades. The company's revenue is concentrated in two blockbuster franchises—the EYLEA ophthalmology drugs and the Dupixent immunology therapy—that together account for over 80% of sales, creating a high-risk, high-reward profile where the successful defense of these franchises against biosimilar and competitive threats determines the entire enterprise value. Co-founders Leonard Schleifer and George Yancopoulos remain in active leadership as board co-chairs, CEO, and Chief Scientific Officer, a governance continuity that has preserved a culture where scientific peer review and genetic validation drive pipeline decisions rather than short-term revenue optimization. With $18.87 billion in cash, a debt-to-equity ratio below 9%, and a commitment to invest $6.6 billion in R&D during 2026, Regeneron possesses the financial capacity to pursue ambitious long-term bets in gene therapy, cell therapy, and obesity that could diversify revenue beyond antibodies, though these modalities remain years from commercial proof. The stock's valuation at 15.5 times trailing earnings reflects investor skepticism about EYLEA's biosimilar defense and Dupixent's patent longevity, even as the company continues to deliver 30% profit margins and industry-leading R&D efficiency.
Leonard S. Schleifer has served as Regeneron's Chief Executive Officer since the company's founding in 1988 and became board co-chair alongside George Yancopoulos in 2023 following the retirement of P. Roy Vagelos. Under his leadership, Regeneron has grown from a two-person startup in a converted Tarrytown industrial space to a $66 billion market-cap biotechnology company with 15 approved medicines and over 15,400 employees. Schleifer's strategic decisions include the 2003 Bayer partnership for EYLEA development, the 2007 Sanofi collaboration that eventually produced Dupixent, and the 2011 IPO that raised capital for commercial infrastructure. He has consistently prioritized R&D investment over short-term margin expansion, with the company's research budget growing from $50 million in the early 1990s to $5.9 billion in 2025. Schleifer is known for maintaining direct involvement in scientific review meetings and pipeline prioritization discussions, a hands-on approach that reflects his medical training and his belief that biotechnology companies fail when commercial executives override scientific judgment. His compensation in 2024 included a base salary of $1.5 million and total compensation of approximately $18 million, with equity awards tied to long-term revenue and pipeline milestones.
George D. Yancopoulos has served as Regeneron's Chief Scientific Officer since 1989 and became board co-chair in 2023, making him one of the longest-serving scientific leaders in the biotechnology industry. Yancopoulos has personally led the development of the VelocImmune, VelociGene, and Veloci-8i2 platforms, which have produced 15 approved medicines and nearly 50 clinical candidates. He has published over 350 scientific papers and holds more than 100 patents covering antibody engineering, trap technologies, and genetic medicine approaches. Yancopoulos played the central scientific role in the discovery of EYLEA, Dupixent, Libtayo, Praluent, and Evkeeza, and he continues to oversee the Regeneron Genetics Center, which has sequenced over 3 million exomes. His 2024 compensation included a base salary of $1.3 million and total compensation of approximately $16 million, with significant equity awards tied to scientific milestones. Yancopoulos is known for attending late-night lab meetings and reviewing primary experimental data personally, maintaining a scientific presence that reinforces the company's culture of rigorous peer review.
Leonard S. Schleifer and George D. Yancopoulos established Regeneron Pharmaceuticals in a converted industrial laboratory in Tarrytown, New York, with initial venture capital funding and the scientific mission of developing neurotrophic factors for neurodegenerative diseases.
Regeneron completed its IPO on the NASDAQ exchange, raising $32 million to fund drug discovery platform development and establishing the financial foundation for three decades of scientific investment.
The FDA approved Arcalyst (rilonacept), Regeneron's first medicine, for Cryopyrin-Associated Periodic Syndromes, validating the company's trap technology and providing the first commercial proof of its platform approach.
The FDA approved EYLEA (aflibercept) for wet age-related macular degeneration, a decision that transformed Regeneron from a development-stage company into a profitable commercial biotechnology firm with a product that would eventually generate $9.6 billion in global annual sales.
The FDA approved Praluent (alirocumab), the first PCSK9 inhibitor developed in collaboration with Sanofi, for heterozygous familial hypercholesterolemia and clinical atherosclerotic cardiovascular disease, entering a new therapeutic market.
The FDA approved Dupixent (dupilumab) for moderate-to-severe atopic dermatitis, marking the beginning of what would become a $17.8 billion global immunology franchise and the first biologic approved for this indication.
The FDA approved Libtayo (cemiplimab) as the first PD-1 inhibitor for metastatic or locally advanced cutaneous squamous cell carcinoma, establishing Regeneron's presence in oncology immunotherapy.
The Regeneron Genetics Center sequenced its 500,000th exome, creating a foundational dataset that would eventually grow to over 3 million exomes and enable the discovery of multiple therapeutic targets including ANGPTL3 and GPR75.
The FDA approved Evkeeza (evinacumab) for homozygous familial hypercholesterolemia, a medicine derived directly from Regeneron Genetics Center discoveries of protective ANGPTL3 loss-of-function variants in less than 1% of sequenced individuals.
Regeneron exercised its option to take full worldwide development, commercialization, and manufacturing rights for Libtayo from Sanofi, ending the profit-sharing arrangement and giving Regeneron direct control over the PD-1 inhibitor's future expansion.
The FDA approved EYLEA HD (aflibercept 8mg) for neovascular age-related macular degeneration and diabetic macular edema, extending the dosing interval to 12-16 weeks and launching the next-generation ophthalmology franchise.
Regeneron completed its acquisition of Decibel Therapeutics for approximately $109 million, adding three gene therapy programs for congenital hearing loss including DB-OTO, which would become the first FDA-approved gene therapy for otoferlin-related deafness.
The European Commission approved Dupixent as the first-ever biologic therapy for uncontrolled chronic obstructive pulmonary disease characterized by raised blood eosinophils, expanding the addressable population by millions of patients.
Regeneron acquired 2seventy bio's preclinical and clinical cell therapy programs for a $5 million upfront payment, forming Regeneron Cell Medicines with approximately 150 transferred employees to advance CAR-T and TCR therapies.
The FDA approved DB-OTO as the first gene therapy for profound congenital hearing loss caused by mutations of the otoferlin gene, marking Regeneron's entry into commercial genetic medicines and validating the Decibel acquisition strategy.
Regeneron acquired Decibel to strengthen its genetic medicines portfolio and gain access to three gene therapy programs for congenital monogenic hearing loss, including the lead candidate DB-OTO. The acquisition built on a six-year collaboration that began in 2017 and was extended in 2021, reflecting Regeneron's strategic decision to expand beyond antibodies into AAV-based therapies for rare diseases where genetic validation provides clear therapeutic targets.
Regeneron acquired 2seventy bio's preclinical and clinical cell therapy programs, including CAR-T and TCR therapies, to form Regeneron Cell Medicines. The transaction complemented Regeneron's antibody and bispecific expertise with cell-based immuno-oncology approaches, enabling combination therapies that pair engineered immune cells with Regeneron's proprietary antibodies.
Regeneron acquired Checkmate Pharmaceuticals to deepen its immuno-oncology portfolio with a novel TLR9 agonist approach designed to activate innate immunity and enhance responses to checkpoint inhibitors like Libtayo.